A Phase 1/2, Open-label, Multicenter, Dose-escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants With Advanced Solid Tumors
A Phase 1/2, Open-label, Multicenter, Dose-escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants With Advanced Solid Tumors is a PHASE1 clinical asset sponsored by Eikon Therapeutics in Advanced Solid Tumors. SEO and diligence focus: EIK1004-001 (IMP1707-001), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Advanced Solid Tumors
Modality: small molecule
Target: EIK1004-001 (IMP1707-001)
Sponsor: Eikon Therapeutics
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 28, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: EIK1004-001 (IMP1707-001)
View original source fields
Condition raw: Advanced Solid Tumors
Condition normalized: Advanced Solid Tumors
Modality raw: small molecule
Modality normalized: small molecule
Target raw: EIK1004-001 (IMP1707-001)
Target normalized: EIK1004-001 (IMP1707-001)